CA2581746A1 - Staphylococcus aureus isd protein-based anti-infectives - Google Patents

Staphylococcus aureus isd protein-based anti-infectives Download PDF

Info

Publication number
CA2581746A1
CA2581746A1 CA002581746A CA2581746A CA2581746A1 CA 2581746 A1 CA2581746 A1 CA 2581746A1 CA 002581746 A CA002581746 A CA 002581746A CA 2581746 A CA2581746 A CA 2581746A CA 2581746 A1 CA2581746 A1 CA 2581746A1
Authority
CA
Canada
Prior art keywords
isd
polypeptide
isda
isdb
isdc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002581746A
Other languages
English (en)
French (fr)
Inventor
David E. Heinrichs
Christie Vermeiren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Western Ontario
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2581746A1 publication Critical patent/CA2581746A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002581746A 2004-10-25 2005-10-25 Staphylococcus aureus isd protein-based anti-infectives Abandoned CA2581746A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62192104P 2004-10-25 2004-10-25
US60/621,921 2004-10-25
PCT/IB2005/004126 WO2006059247A2 (en) 2004-10-25 2005-10-25 VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC

Publications (1)

Publication Number Publication Date
CA2581746A1 true CA2581746A1 (en) 2006-06-08

Family

ID=36565416

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002581746A Abandoned CA2581746A1 (en) 2004-10-25 2005-10-25 Staphylococcus aureus isd protein-based anti-infectives

Country Status (6)

Country Link
EP (1) EP1812066A4 (enExample)
JP (1) JP2008517900A (enExample)
KR (1) KR20070085457A (enExample)
AU (1) AU2005310981A1 (enExample)
CA (1) CA2581746A1 (enExample)
WO (1) WO2006059247A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597997A (en) 2005-02-14 2013-10-25 Epitopix Llc Antibody compositions that bind polypeptides from staphylococcus aureus
AU2007281934B2 (en) * 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
NZ570805A (en) 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
CA2667788A1 (en) * 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
KR20100072228A (ko) 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
NZ614557A (en) * 2009-03-23 2015-03-27 Epitopix Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
HRP20160274T1 (hr) 2009-04-03 2016-04-08 University Of Chicago Pripravci i metode vezane za varijante proteina a (spa)
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
WO2014144423A2 (en) * 2013-03-15 2014-09-18 Techulon Inc. Antisense molecules for treatment of staphylococcus aureus infection
US9834768B2 (en) 2014-12-31 2017-12-05 Korea Advanced Institute Of Science And Technology Effective method for specific gene silencing using artificial small RNA
CA3139981A1 (en) 2019-05-14 2020-11-19 The University Of Chicago Methods and compositions comprising staphylococcus protein a (spa) variants
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections
CN120943954B (zh) * 2025-10-20 2026-02-06 重庆原伦生物科技有限公司 抗金黄色葡萄球菌IsdB抗体的制备及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002306849A1 (en) * 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
EP2339344A1 (en) * 2001-06-15 2011-06-29 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
EP1412379B1 (en) * 2001-08-02 2012-01-25 The University Of Sheffield Vaccine
NZ544542A (en) * 2003-07-24 2009-01-31 Merck & Co Inc Polypeptides for inducing a protective immune response against staphylococcus aureus
ES2730275T3 (es) * 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos

Also Published As

Publication number Publication date
EP1812066A2 (en) 2007-08-01
WO2006059247A2 (en) 2006-06-08
EP1812066A4 (en) 2010-06-30
KR20070085457A (ko) 2007-08-27
AU2005310981A1 (en) 2006-06-08
WO2006059247A8 (en) 2007-04-26
JP2008517900A (ja) 2008-05-29
WO2006059247A3 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
WO2008152447A2 (en) Staphylococcus aureus specific anti-infectives
EP1812066A2 (en) Staphylococcus aureus isd protein-based anti-infectives
CA2412504C (en) Antigenic polypeptides
US8067015B2 (en) Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
JP2001505415A (ja) Streptococcus pneumoniaeの抗原およびワクチン
Korem et al. Characterization of RAP, a quorum sensing activator of Staphylococcus aureus
US20080050361A1 (en) Staphylococcus aureas specific anti-infectives
SG182975A1 (en) Pseudomonas aeruginosa outer membrane protein pa4710
Hughes et al. Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59
DK1784220T3 (en) BACTERIAL OBJECTIVES TO ACHIEVE IRON
US8729013B2 (en) Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus
JPH10113189A (ja) 新規 RNaseP
WO2006043182A2 (en) Screening assays for inhibitors of a staphylococcus aureus siderophore
US20100129349A1 (en) Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus
US20070292873A1 (en) Bacterial iron acquisition targets
JPH11235183A (ja) シグナル認識粒子ポリペプチドおよびポリヌクレオチド
EP4647443A1 (en) Therapeutic variable domain of heavy chain (vhh) antibody fusions co-neutralizing alpha- and gamma-hemolysins from staphylococcus aureus
US7588773B2 (en) Methods and compositions for diagnosing and preventing a group B streptococcal infection
JP2001514025A (ja) 新規rnasep
JP2002525048A (ja) Rnasepポリペプチド
WO2008127102A1 (en) S. pnuemoniae transcytosis protein
KR20230051416A (ko) 신규한 항-seb 항체 또는 이의 항원 결합 단편, 및 이의 용도
AU2013205400A1 (en) Antigenic Polypeptides

Legal Events

Date Code Title Description
FZDE Discontinued